0 %

Galactosemia TGAL

fluo

The NEONATAL T-GAL Screening Fluo is an enzymatic test for the fluorescence detection of D-galactose and galactose-1-phosphate in the context of neonatal screening for galactosemia. This quantitative test is performed from a drop of blood dried on blotting paper type 903® and 226.

This assay is dedicated to professional use in diagnostic laboratories. The device is not for self-testing.

Total Galactose, extracted from newborn samples, is metabolized by enzymatic complexes, resulting in the production of NADH. NADH serves as a co-factor in the reduction of resazurin to resorufin, catalyzed by the enzyme diaphorase. The intensity of the resorufin fluorescent signal is directly proportional to the concentration of total galactose in the sample.

General information

Format: 288 – 576 determinations
Storage: At 2-8°C
Possible automation: Yes
Turn around time: Less than 1.5 hour

Test principle

Galactosemia is defined by an alteration in the metabolism of galactose, caused by a deficient activity of one of the three enzymes involved in its metabolism. Conventional galactosemia, due to complete galactose-1-phosphate uridyl transferase (GALT) deficiency, is the most common and produces the most severe galactosemia symptoms in infants. Two other much rarer forms of galactosemia exist, galactokinase (GALK) and UDP-galactose epimerase (GALE) deficiencies. The genes involved are GALTGALK1 and GALE, respectively.

Conventional galactosemia is a severe disease that begins when a person swallows milk through eating disorders, lethargy, growth failure, and severe liver and kidney damage. Neonatal sepsis may also occur. A cataract appears within days or weeks. In the longer term, learning difficulties and ovarian failure in girls may occur. Partial deficits, due to a relatively common GALT mutation, called “Duarte”, have a much less severe clinical presentation, which may even remain asymptomatic.

GALK deficiency is responsible for isolated cataracts. GALE deficiency manifests itself as a variable clinical presentation resembling classical galactosemia.

The neonatal screening programs for galactosemia are traditionally based on a total galactose assay and/or GALT activity.

The main objective of long-term treatment of classical galactosemia is to minimize the dietary intake of galactose. This dietary management protects against liver and renal complications, as well as cataracts. However, it does not prevent learning difficulties and hormone disorders from appearing. A follow-up is required and focuses on psychomotor development and gonadal function.

Disease

Advantages

icon fast
75-minute incubation time
icon adaptability
Protocol available for manual and automated procedures
icon easy-to-use
No transfer step required
icon practical
Protocol identical to the NEONATAL MSUD Screening Fluo and NEONATAL PKU Screening Fluo kits
icon complementary
Can be used in combination with the NEONATAL GAL-T Screening Fluo for the confirmation of galactosemia
icon accurate
Quantitative test with controls and calibration curves supplied on blotting paper
icon sensitivity
Increased sensitivity of the test due to the use of the fluorescence technique
icon certified quality
European production according to ISO quality criteria and CE marking

Linked products

LaCar
The NEONATAL GAL-T Screening Fluo is an enzymatic assay for the quantitative determination of galactose-1-phosphate uridyltransferase (GAL-T) activity levels.
LaCar
The NEONATAL Total-Galactose Screening Assay is an enzymatic test used to quantify total galactose (galactose and galactose-1-phosphate) as part of neonatal screening for galactosemia.
Your ultimate ally for fully automated and precise neonatal diagnostics!

You have a question regarding our products ? You want to know more about our method ?

Find out about our other expertises

Genetic testing CE Kits
Pharmacogenetics
Contact